Adaptimmune Therapeutics plc (ADAP)

Etorro trading 970x250
Adaptimmune Therapeutics plc (ADAP) Logo

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

Adaptimmune Therapeutics plc News and around…

Latest news about Adaptimmune Therapeutics plc (ADAP) common stock and company :

2 Top Healthcare Stocks That Could Be Bought Out in 2022
16 Oct, 2021 Yahoo! Finance

The healthcare sector has been a serious disappointment for investors in 2021. After a banner year in 2020 thanks to the advent of several highly lucrative COVID-19 vaccines and therapies, the closely watched SPDR S&P Biotech ETF (NYSEMKT: XBI) has now fallen by a staggering 11.5% so far this year. A healthy cadre of headline-grabbing new technologies from biotech pioneers such as Allogene Therapeutics, Bluebird Bio, CRISPR Therapeutics (NASDAQ: CRSP), Sarepta Therapeutics, among many others, have failed to live up to expectations and/or exhibited worrying safety signals.

Interesting ADAP Put And Call Options For June 2022
15 Oct, 2021 FinancialContent

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options begin trading this week, for the June 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
05 Oct, 2021 Yahoo! Finance

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - - Translational data from Phase 1 SURPASS trial to be presented at SITC - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2

Could The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ownership Structure Tell Us Something Useful?
04 Oct, 2021 Yahoo! Finance

If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...

3 Biotech Stocks That Could Make You Filthy Rich
27 Sep, 2021 FinancialContent

These three low-priced cancer stocks could be grossly undervalued.

Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?
24 Sep, 2021 Yahoo! Finance

Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Sum Up The Pieces: MOON Could Be Worth $46
20 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.21 per unit.

Why Adaptimmune Therapeutics Was Sinking This Week
17 Sep, 2021 FinancialContent

Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.

First Week of November 19th Options Trading For Adaptimmune Therapeutics (ADAP)
17 Sep, 2021 FinancialContent

Investors in Adaptimmune Therapeutics PLC (ADAP) saw new options begin trading this week, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new November 19th contracts and identified one put and one call contract of particular interest.

Looking Into Adaptimmune Therapeutics's Return On Capital Employed
14 Sep, 2021 FinancialContent

Adaptimmune Therapeutics (NASDAQ:ADAP) brought in sales totaling $3.10 million during Q2 according to data provided by Benzinga ...

Adaptimmune Shares Encouraging Data From Solid Tumor Trial
13 Sep, 2021 FinancialContent

Adaptimmune Therapeutics plc(NASDAQ: ADAP) hasannounced updated datafrom its Phase 1 SURPASS trial in multiple ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
13 Sep, 2021 FinancialContent

Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The ...

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
13 Sep, 2021 FinancialContent
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
08 Sep, 2021 Yahoo! Finance

Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies
08 Sep, 2021 Yahoo! Finance

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

72 Biggest Movers From Yesterday
08 Sep, 2021 FinancialContent

Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, ...

Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher
07 Sep, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded down 0.65% to 35,138.64 while the NASDAQ rose 0.13% to 15,383.18. The S&P also ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
07 Sep, 2021 FinancialContent

Gainers Surrozen (NASDAQ:SRZN) stock rose 33.14% to $9.64 during Tuesday's regular session. The company's market ...

45 Stocks Moving In Tuesday's Mid-Day Session
07 Sep, 2021 FinancialContent

Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares ...

Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
07 Sep, 2021 FinancialContent

A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
07 Sep, 2021 FinancialContent

Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The ...

Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
07 Sep, 2021 FinancialContent

Adaptimmune Therapeutics plc(NASDAQ: ADAP) has announced acollaboration and license agreementwithGenentech, a ...

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
07 Sep, 2021 FinancialContent
Adaptimmune Stock Soars on Roche Pact to Commercialize Cancer Therapy
07 Sep, 2021 Yahoo! Finance

By Dhirendra Tripathi

Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
06 Sep, 2021 Yahoo! Finance

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
05 Sep, 2021 FinancialContent
ADAP Makes Bullish Cross Above Critical Moving Average
25 Aug, 2021 FinancialContent

In trading on Wednesday, shares of Adaptimmune Therapeutics PLC (ADAP) crossed above their 200 day moving average of $4.91, changing hands as high as $5.19 per share. Adaptimmune Therapeutics PLC shares are currently trading up about 13% on the day..

Why Adaptimmune Therapeutics Stock Is Spiking Today
23 Aug, 2021 FinancialContent

The hunt for the next biotech buyout play is apparently underway.

Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock Options
16 Aug, 2021 Yahoo! Finance

Investors need to pay close attention to for Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Transcript
09 Aug, 2021 FinancialContent

ADAP earnings call for the period ending June 30, 2021.

Adaptimmune Therapeutics plc (ADAP) is a NASDAQ Common Stock listed in , ,

970x250